Trials
4 active
6 in total · 1 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Participants will receive one RAP-219 0.125 mg capsule daily for 3 days followed by one 0.25mg tablet RAP-219 daily for 28 days, then one 0.75mg tablet daily for the remainder of the treatment period.”In the company’s words, NCT07219407 on ClinicalTrials.gov
- Tested for
- Epilepsy (4 trials), Focal Seizure (3 trials), Focal Epilepsy (3 trials), Refractory Focal Epilepsy, Seizure, Focal Onset Seizure
- Main trialPhase 3
- “This is a clinical research study for an investigational drug called RAP-219 in adult participants with focal seizures. This study is being conducted to determine if RAP-219 is safe and effective in reducing focal seizure frequency.”In the company’s words, NCT07563881 on ClinicalTrials.gov
Other drugs for Epilepsy
- BHV-7000Biohaven · Phase 2/3
- ElsunersenPraxis Precision Medicines · Phase 3
- LP352Longboard Pharmaceuticals · Phase 3
- PRAX-562Praxis Precision Medicines · Phase 3
- VormatroginePraxis Precision Medicines · Phase 3
- EverolimusNovartis Pharmaceuticals · Phase 3
Coming up4
- Jun 2027Phase 1 trial completes · ClinicalTrials.gov
- 3 Feb 2028Phase 2 trial completes · ClinicalTrials.gov
- Jul 2029Phase 3 trial completes · ClinicalTrials.gov
- Jul 2029Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials6
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Jul 2029 | Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1 | |
| Phase 3Recruiting | Jul 2029 | Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures | |
| Phase 2Recruiting | 3 Feb 2028 | A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures | |
| Phase 1Recruiting | Jun 2027 | Study Designed to Evaluate the Safety, Tolerability, and PK of RAP-219 Formulated as an Long Acting Injectable. | |
| Phase 2Completed | 26 Sep 2025 | Study Evaluating the Safety and Efficacy of RAP-219 in Adult Participants With Refractory Focal Epilepsy | |
| Phase 2Completed | 5 Aug 2026 | Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Bipolar I Disorder |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026